LGVN Stock Forecast: Longeveron, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Longeveron, Inc. is $80. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Longeveron, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (7): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LGVN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LGVN, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | Maxim Group | Downgrade | Hold | — |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $8.00 |
| 15 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | Roth MKM | Initiates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2024 | Maxim Group | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 July 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 1 June 2023 | EF Hutton | Assumes | Buy | $13 |
| 16 May 2023 | EF Hutton | Reiterates | Buy | — |
| 9 May 2023 | EF Hutton | Reiterates | Buy | — |
| 27 Mar 2023 | EF Hutton | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LGVN.
This page is one stock. Monday covers all of them.
LGVN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LGVN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 4.7×
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 22% of US stocks
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- −9.2%
- Earnings growth (YoY)
- —
- Gross margin
- 63.4%
- Operating margin
- —
- Net margin
- —
Higher than 17% of US stocks
Higher than 76% of US stocks
- Return on equity
- −203.6%
- Return on assets
- −90.9%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Longeveron, Inc. has a market value of $5.6M.
Revenue in the twelve months to 30 June 2026: $1.2M. The latest quarter shrank 9.2% year on year.
Net income over the same four quarters: −$23.5M, a −1977.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$20.7M.
Longeveron, Inc. employs 38 people — $31K of revenue per employee.
Data provided by Twelve Data
LGVN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LGVN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Longeveron, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LGVN
What is the LGVN stock price forecast for 2026-2027?
The median 12-month analyst price target for Longeveron, Inc. is $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LGVN stock a buy right now?
Of the 1 analyst covering Longeveron, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Longeveron, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LGVN?
As at 21 Nov 2026, Longeveron, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).
Will LGVN stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $80, and Ticker Nerd's factor model ranks Longeveron, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LGVN stock forecast for 2030?
No analyst covering Longeveron, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $80 over the next 12 months.
What does Longeveron, Inc. do?
Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions.
About Longeveron, Inc.
Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions. Its current programs center on Lomecel-B, a lead investigational therapy being studied across several clinical indications, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron’s work spans cell therapy research, clinical development, and translational medicine, placing it within the broader biotechnology sector. Headquartered in Miami, Florida, Longeveron serves as a specialized player in the market for advanced biological treatments aimed at unmet medical needs.
CEO Mr. Stephen H. Willard Esq. · 38 employees · United States · https://longeveron.com